Prescription Drug Price Relief Act of 2019
- Last Action
- 1/25/2019
Actions
- 2019-01-25Referred to the Subcommittee on Health.
- 2019-01-10Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- 2019-01-10Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2019-01-10Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2019-01-10Introduced in House
- 2019-01-10Introduced in House
CRS Summary
As of 2019-01-10 (00)
Prescription Drug Price Relief Act of 2019
This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.
Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population.
The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
Cosponsors (20)
- Peter Welch (D-VT)
- ELIJAH CUMMINGS (D-MD)
- Alexandria Ocasio-Cortez (D-NY)
- JANICE SCHAKOWSKY (D-IL)
- Mark Pocan (D-WI)
- Ilhan Omar (D-MN)
- ROSA DELAURO (D-CT)
- Joe Neguse (D-CO)
- BARBARA LEE (D-CA)
- Rashida Tlaib (D-MI)
- Ayanna Pressley (D-MA)
- Tulsi Gabbard (D-HI)
- PETER DEFAZIO (D-OR)
- Pramila Jayapal (D-WA)
- Mark DeSaulnier (D-CA)
- ELEANOR NORTON (D-DC)
- Debra Haaland (D-NM)
- Debbie Mucarsel-Powell (D-FL)
- DANNY DAVIS (D-IL)
- Jamie Raskin (D-MD)
Subjects
- Administrative remedies
- Asia
- Business records
- Canada
- Civil actions and liability
- Competition and antitrust
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Europe
- France
- Germany
- Government information and archives
- Government studies and investigations
- Health care costs and insurance
- Health information and medical records
- Inflation and prices
- Intellectual property
- Japan
- Licensing and registrations
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.